通过向首席执行官Eric Leire发行4 000万股股份,Gentral Biosciences筹集了440 000英镑,10月16日将股票列入LSE。 Genflow Biosciences raised £440,000 by issuing 40 million shares to CEO Eric Leire, with shares set to list on the LSE on Oct. 16.

2025年10月9日,Genflow Biosciences PLC终止了最初的股份订阅计划,并完成了新的股票发行,通过向CEO Eric Leire各发行1.1便士的4 000万股,在支出前筹集了440 000英镑。 Genflow Biosciences PLC terminated its initial share subscription plan and completed a new equity issuance on October 9, 2025, raising £440,000 before expenses by issuing 40 million shares at 1.1 pence each to CEO Eric Leire. Leire将保留450万股,并向现有股东转让3 550万股。 Leire will retain 4.5 million shares and transfer 35.5 million to existing shareholders. 双方都收到了 24 个月的认股权证，可以每股 1.2 便士的价格行使。 Both parties received 24-month warrants exercisable at 1.2 pence per share. 预计这些股票将于10月16日被接纳进入伦敦证券交易所的主要市场,发行的股票总额增加到493 547 942美元。 The shares are expected to be admitted to the London Stock Exchange’s main market on October 16, increasing total issued shares to 493,547,942. 该公司说,替代交易对股东没有那么好,而且对股东更加有利。 The company stated the alternative transaction is less dilutive and more favorable to shareholders. 该公告载有根据《联合王国市场滥用条例》提供的内部信息。 The announcement contains inside information under UK Market Abuse Regulation.